Recap: DarioHealth Q2 Earnings

 

Shares of DarioHealth DRIO fell 0.5% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were unchanged 0.00% over the past year to ($0.68), which beat the estimate of ($0.85).

Revenue of $5,261,000 rose by 194.40% from the same period last year, which beat the estimate of $5,110,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 16, 2021

Time: 08:30 AM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/46226/indexl.html

Price Action

52-week high: $31.85

Company's 52-week low was at $10.01

Price action over last quarter: down 19.78%

Company Description

DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!